AUTHORS
Kim Jae-Sung, PhD, Jaehyung Cho, PhD2, Gavriel Brown3, Robert A Campbell, PhD4, Babak Razani5
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
ABSTRACT
Receptor-interacting protein Ser/Thr kinase 1 (RIPK1) functions as a molecular switch for inflammation and cell death in nucleated cells. However, its role in anucleate platelets and arterial thrombosis remains unknown. Using intravital microscopy in megakaryocyte-specific Ripk1 knockout (KO; Ripk1fl/fl;Pf4-Cre) mice, we demonstrated that platelet RIPK1 promotes platelet thrombus formation without affecting fibrin generation at sites of laser-induced cremaster arteriolar thrombosis. In a FeCl3-induced carotid arterial thrombosis model, the time to occlusion was delayed in Ripk1 KO mice. In contrast, bleeding times and blood loss at the site of tail-tip amputation were not altered in the KO mice. Furthermore, Ripk1 KO mice exhibited improved neurological outcomes and reduced infarct volume following focal brain ischemia, compared with wild-type (WT) mice. Deletion of platelet RIPK1 reduced P-selectin exposure, αIIbβ3 integrin activation, and platelet aggregation induced by low concentrations of various agonists, but not ADP. Importantly, the functional defects in Ripk1-null platelets were rescued by the addition of ADP, suggesting that platelet RIPK1 enhances granule secretion-mediated platelet function and thrombus formation. Agonist-induced phosphatidylserine exposure was not altered by RIPK1 deletion, consistent with unchanged fibrin generation in intravital microscopy. Unlike in other cell types, where RIPK1-Ser166 phosphorylation is required for its kinase activity, we found that RIPK1-Ser166 is not phosphorylated during platelet activation, and Nec-1s, a RIPK1-specific inhibitor that blocks RIPK1-Ser166 phosphorylation, did not affect platelet activation and aggregation, indicating that RIPK1 enhances platelet activation independent of its kinase activity. Instead, we identified RIPK1-Ser320 in humans and Ser321 in mice as a novel phosphorylation site during platelet activation. This Ser residue was phosphorylated as early as 1-5 minutes after thrombin or CRP stimulation. Using a combination of pharmacologic and genetic approaches, we found that p38-MK2 signaling phosphorylates RIPK1-Ser320/321. Importantly, RIPK1-Ser321 phosphorylation was detected in the FeCl3-induced carotid arterial thrombus. Because of the lack of inhibitors blocking RIPK1-Ser320/321 phosphorylation, we generated RIPK1-deficient human CD34+ megakaryocytes (MKs) using CRISPR/Cas9. The RIPK1 KO MKs exhibited reduced P-selectin exposure, and this defect was rescued by overexpressing WT RIPK1 but not the Ser320Ala mutant. Furthermore, using bone marrow MKs from WT and Ripk1 KO mice, we found that Ripk1-null MKs exhibited reduced α-granule secretion following agonist stimulation, and this defect was rescued by transfection with WT RIPK1 but not the Ser321Ala mutant. Collectively, these results suggest that platelet RIPK1 enhances granule secretion and platelet aggregation through Ser320/321 phosphorylation mediated by p38-MK2 signaling, contributing to arterial thrombosis.
DISCLOSURES
Kim Jae-Sung, PhD: No relevant conflicts of interest to declare.